MRNA vaccine takes on Hard-to-Treat cancers
NCT ID NCT07363369
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a therapeutic mRNA vaccine that targets a protein called FAP found on cancer-supporting cells. The goal is to help the immune system attack the tumor's defenses. Ten adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) who have run out of standard options will receive the vaccine along with immune checkpoint inhibitors. The main focus is safety, but researchers will also look for signs of tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- FAP mRNA vaccine combined with immune checkpoint inhibitors
- What this could lead to
- If it works, this could point toward a new treatment option for advanced solid tumors that have stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 10 participants, so it is primarily testing safety. The vaccine may not shrink tumors or improve survival, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo targets Hard-to-Treat cancers
- New drug combo takes on advanced cancers
- Experimental injection trains immune cells inside the body to fight cancer
- New combo therapy takes on advanced cancers
- New hope for advanced cancer patients as experimental drug JSKN021 enters first human tests
- New drug CS231295 enters first human trial for tough cancers